BRPI0507177A - agonistas (vpac2) do receptor peptìdico de ativação de adenilato ciclase pituitários (pacap) e seus métodos farmacológicos de uso - Google Patents
agonistas (vpac2) do receptor peptìdico de ativação de adenilato ciclase pituitários (pacap) e seus métodos farmacológicos de usoInfo
- Publication number
- BRPI0507177A BRPI0507177A BRPI0507177-1A BRPI0507177A BRPI0507177A BR PI0507177 A BRPI0507177 A BR PI0507177A BR PI0507177 A BRPI0507177 A BR PI0507177A BR PI0507177 A BRPI0507177 A BR PI0507177A
- Authority
- BR
- Brazil
- Prior art keywords
- vpac2
- pacap
- adenylate cyclase
- agonists
- pharmacological methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 108060000200 adenylate cyclase Proteins 0.000 title abstract 2
- 230000000144 pharmacologic effect Effects 0.000 title abstract 2
- 102000005962 receptors Human genes 0.000 title abstract 2
- 108020003175 receptors Proteins 0.000 title abstract 2
- 101800001401 Activation peptide Proteins 0.000 title 1
- 102400000069 Activation peptide Human genes 0.000 title 1
- 101150060255 MZB1 gene Proteins 0.000 title 1
- 101100462550 Mus musculus Adcyap1 gene Proteins 0.000 title 1
- 102000030621 adenylate cyclase Human genes 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 230000001817 pituitary effect Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 102100038286 Vasoactive intestinal polypeptide receptor 2 Human genes 0.000 abstract 2
- 239000008103 glucose Substances 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 239000000018 receptor agonist Substances 0.000 abstract 2
- 229940044601 receptor agonist Drugs 0.000 abstract 2
- 101000666868 Homo sapiens Vasoactive intestinal polypeptide receptor 2 Proteins 0.000 abstract 1
- 229940122199 Insulin secretagogue Drugs 0.000 abstract 1
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 abstract 1
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 abstract 1
- 101710137651 Vasoactive intestinal polypeptide receptor 2 Proteins 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 208000016097 disease of metabolism Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000003914 insulin secretion Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53955004P | 2004-01-27 | 2004-01-27 | |
| US56649904P | 2004-04-29 | 2004-04-29 | |
| PCT/US2005/002609 WO2005072385A2 (en) | 2004-01-27 | 2005-01-27 | Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0507177A true BRPI0507177A (pt) | 2007-06-26 |
Family
ID=34830483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0507177-1A BRPI0507177A (pt) | 2004-01-27 | 2005-01-27 | agonistas (vpac2) do receptor peptìdico de ativação de adenilato ciclase pituitários (pacap) e seus métodos farmacológicos de uso |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090143283A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1713493A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2007519739A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20070009554A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005208911A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0507177A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2554475A1 (cg-RX-API-DMAC7.html) |
| EC (1) | ECSP066793A (cg-RX-API-DMAC7.html) |
| IL (1) | IL176705A0 (cg-RX-API-DMAC7.html) |
| MA (1) | MA28335A1 (cg-RX-API-DMAC7.html) |
| NO (1) | NO20063801L (cg-RX-API-DMAC7.html) |
| RU (1) | RU2006130691A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005072385A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101001639A (zh) * | 2004-06-12 | 2007-07-18 | 拜尔药品公司 | 血管活性肠肽(vip)/垂体腺苷酸环化酶活化肽(pacap)受体2(vpac2)激动剂的聚乙二醇化和使用方法 |
| EP1896048A4 (en) * | 2005-05-06 | 2010-11-03 | Bayer Pharmaceuticals Corp | PEPTIDE RECEPTOR (VPAC2) AGONISTS THAT ACTIVATE HYPOPHYSIC ADENYLATE CYCLASE (PACAP) AND THEIR PHARMACOLOGICAL METHODS OF USE |
| AU2006306236B2 (en) | 2005-10-26 | 2011-12-01 | Eli Lilly And Company | Selective VPAC2 receptor peptide agonists |
| WO2011133948A2 (en) | 2010-04-22 | 2011-10-27 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
| US9789164B2 (en) | 2013-03-15 | 2017-10-17 | Longevity Biotech, Inc. | Peptides comprising non-natural amino acids and methods of making and using the same |
| CA2983030A1 (en) | 2015-04-16 | 2016-10-20 | Alder Biopharmaceuticals, Inc. | Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia |
| MX2018012470A (es) | 2016-04-15 | 2019-07-01 | Alder Biopharmaceuticals Inc | Anticuerpos anti pacap humanizados y usos de ellos. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU656230B2 (en) * | 1991-10-11 | 1995-01-27 | F. Hoffmann-La Roche Ag | Cyclic vasoactive peptides |
| ES2307534T3 (es) * | 1999-09-28 | 2008-12-01 | Bayer Corporation | Agonistas de receptores 3 (r3) del peptido activador de la adenilato ciclasa hipofisiaria (pacap) y sus metodos de uso farmacologicos. |
| US20050009739A1 (en) * | 2002-02-14 | 2005-01-13 | Wei Wang | Formulation strategies in stabilizing peptides in organic solvents and in dried states |
| CA2491279A1 (en) * | 2002-07-12 | 2004-01-22 | Bayer Pharmaceuticals Corporation | Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use |
-
2005
- 2005-01-27 KR KR1020067015124A patent/KR20070009554A/ko not_active Withdrawn
- 2005-01-27 EP EP05712166A patent/EP1713493A4/en not_active Withdrawn
- 2005-01-27 AU AU2005208911A patent/AU2005208911A1/en not_active Abandoned
- 2005-01-27 CA CA002554475A patent/CA2554475A1/en not_active Abandoned
- 2005-01-27 US US10/586,124 patent/US20090143283A1/en not_active Abandoned
- 2005-01-27 BR BRPI0507177-1A patent/BRPI0507177A/pt not_active IP Right Cessation
- 2005-01-27 RU RU2006130691/15A patent/RU2006130691A/ru not_active Application Discontinuation
- 2005-01-27 JP JP2006551478A patent/JP2007519739A/ja active Pending
- 2005-01-27 WO PCT/US2005/002609 patent/WO2005072385A2/en not_active Ceased
-
2006
- 2006-07-04 IL IL176705A patent/IL176705A0/en unknown
- 2006-07-24 MA MA29206A patent/MA28335A1/fr unknown
- 2006-08-25 EC EC2006006793A patent/ECSP066793A/es unknown
- 2006-08-25 NO NO20063801A patent/NO20063801L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20063801L (no) | 2006-10-26 |
| JP2007519739A (ja) | 2007-07-19 |
| AU2005208911A1 (en) | 2005-08-11 |
| WO2005072385A3 (en) | 2006-06-08 |
| WO2005072385A2 (en) | 2005-08-11 |
| MA28335A1 (fr) | 2006-12-01 |
| RU2006130691A (ru) | 2008-03-10 |
| EP1713493A2 (en) | 2006-10-25 |
| US20090143283A1 (en) | 2009-06-04 |
| IL176705A0 (en) | 2006-10-31 |
| CA2554475A1 (en) | 2005-08-11 |
| KR20070009554A (ko) | 2007-01-18 |
| EP1713493A4 (en) | 2009-06-24 |
| ECSP066793A (cg-RX-API-DMAC7.html) | 2006-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0312621A (pt) | Agonistas de receptor (vpac2) de peptìdeo de ativação de pituitária adenilato ciclase (pacap) | |
| ES2930750T3 (es) | Composición farmacéutica para tratar un síndrome metabólico | |
| EP1909824B1 (en) | Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent | |
| JP6581606B2 (ja) | 選択的グルカゴン受容体アゴニストとしてのエキセンジン−４誘導体 | |
| MY131983A (en) | Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use | |
| ES2653765T3 (es) | Agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón | |
| US20140142023A1 (en) | Pharmaceutical Composition for Treating A Metabolic Syndrome | |
| JP2017519718A (ja) | ペプチド二重ｇｌｐ−１／グルカゴン受容体アゴニストとしてのエキセンジン−４誘導体 | |
| KR20120062777A (ko) | 변형된 혈관활성 장 펩티드 | |
| Kim et al. | Low molecular weight (1 kDa) polyethylene glycol conjugation markedly enhances the hypoglycemic effects of intranasally administered exendin-4 in type 2 diabetic db/db mice | |
| US20200115430A1 (en) | Human amylin analog polypeptides and methods of use | |
| CN110769812A (zh) | 用于施用胰高血糖素样肽类似物的微针系统 | |
| Sun et al. | Site-specific fatty chain-modified exenatide analogs with balanced glucoregulatory activity and prolonged in vivo activity | |
| BRPI0507177A (pt) | agonistas (vpac2) do receptor peptìdico de ativação de adenilato ciclase pituitários (pacap) e seus métodos farmacológicos de uso | |
| Han et al. | Rational design of dimeric lipidated Xenopus glucagon-like peptide 1 analogues as long-acting antihyperglycaemic agents | |
| Huang et al. | S3-2, a novel long-lasting oxyntomodulin derivative, exerts improvement on diabesity and renal injury through activating GLP-1 and glucagon receptors | |
| TW200716156A (en) | Pituitary adenylate cyclase activating peptide (PACAP) receptor (VPAC2) agonists and their pharmacological methods of use | |
| Skurikhin et al. | Effects of Pegylated Glucagon-Like Peptide-1 Analogue in C57Bl/6 Mice under Optimal Conditions and During Streptozotocin-Induced Diabetes | |
| Son et al. | Chemical chaperone-conjugated exendin-4 as a cytoprotective agent for pancreatic β-cells | |
| Bavec | (Poly) peptide-based therapy for diabetes mellitus: Insulins versus incretins | |
| Khalil et al. | A Review on the Strategies of Treatment of Type-2 Diabetes Mellitus: Focus on Vildagliptin | |
| Mora | Basal Insulins. | |
| Jing et al. | Biological activity studies of the novel glucagon-like peptide-1 derivative HJ07 | |
| Mathieu | Engineering basal insulin—clinical evidence translating to clinical experience | |
| Hargrove et al. | Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADES |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011. |